...

首页> 外文期刊>Leukemia Research: A Forum for Studies on Leukemia and Normal Hemopoiesis >INVESTIGATION ON THE FREQUENCY OF CD10, CD30, BCL-2, BCL-6, MUM-1, P53, KI-67 AND IMPACT TO THE PROGNOSIS IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA

【24h】

INVESTIGATION ON THE FREQUENCY OF CD10, CD30, BCL-2, BCL-6, MUM-1, P53, KI-67 AND IMPACT TO THE PROGNOSIS IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA

机译：弥漫性大B细胞淋巴瘤患者CD10，CD30，BCL-2，BCL-6，MUM-1，P53，KI-67的频率及其对预后的影响

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Leukemia Research: A Forum for Studies on Leukemia and Normal Hemopoiesis》 |2014年第1期|共1页
作者
Haciboncuk P.; Yilmaz M.; Soylu G.; Gundogan E.; Acik D. Yanardag; Okan V.; Pehlivan M.; Sahin H. H.; Kul S.; Sari I.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. CD10,Bcl-6,CD138,Bcl-2,MUM1在136例弥漫大B细胞淋巴瘤中的表达及预后意义 [J] . Yan Song, Zhi Cao, Qin Su, 中德临床肿瘤学杂志（英文版） . 2009,第010期
2. INVESTIGATION ON THE FREQUENCY OF CD10, CD30, BCL-2, BCL-6, MUM-1, P53, KI-67 AND IMPACT TO THE PROGNOSIS IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA [J] . Haciboncuk P., Yilmaz M., Soylu G., Leukemia Research: A Forum for Studies on Leukemia and Normal Hemopoiesis . 2014,第Suppla1期

机译：弥漫性大B细胞淋巴瘤患者CD10，CD30，BCL-2，BCL-6，MUM-1，P53，KI-67的频率及其对预后的影响
3. Evaluation of BCL-6, CD10, CD138 and MUM-1 Expression in Diffuse Large B-Cell Lymphoma patients: CD138 is a Marker of Poor Prognosis [J] . Asian Pacific Journal of Cancer Prevention . 2012,第7期

机译：弥漫性大B细胞淋巴瘤患者中BCL-6，CD10，CD138和MUM-1表达的评估：CD138是不良预后的标志
4. Expression profile of CD10, Bcl-6, CD138, Bcl-2 and MUM1 and their prognostic value in 136 patients with diffuse large B-cell lymphoma [J] . Yan Song, Zhi Cao, Qin Su, 中德临床肿瘤学杂志：英文版 . 2009,第010期

机译：136例弥漫性大B细胞淋巴瘤患者CD10，Bcl-6，CD138，Bcl-2和MUM1的表达谱及其预后价值
5. Survival Prediction in Patients with Diffuse Large B-cell Lymphoma Using Logistic and Neural Network Models [C] . Chin-Chuan Chang, Chien-Hua Chen, Jer-Guang Hsieh, IEEE Eurasia Conference on Biomedical Engineering, Healthcare and Sustainability . 2021

机译：逻辑和神经网络模型弥漫性大B细胞淋巴瘤患者的存活预测
6. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018

机译：免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性：RU051417I-R-ICE（利妥昔单抗-异环磷酰胺-卡铂-依托泊苷）与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤（DLBCL）。
7. Correlation Between C-MYC, BCL-2, and BCL-6 Protein Expression and Gene Translocation as Biomarkers in Diagnosis and Prognosis of Diffuse Large B-cell Lymphoma [O] . YunXiang Zhang, Hui Wang, Cuiai Ren, 2018

机译：C-MYC，BCL-2和BCL-6蛋白表达与基因易位性作为生物标志物在弥漫性大B细胞淋巴瘤诊断和预后中的相关性
8. Serum levels of inflammatory cytokines at diagnosis correlate to the bcl-6 and CD10 defined germinal centre (GC) phenotype and bcl-2 expression in patients with diffuse large B-cell lymphoma [O] . Pedersen Lars M, Jürgensen Gitte W, Johnsen Hans E 2005

机译：诊断时血清炎性细胞因子水平与弥漫性大B细胞淋巴瘤患者bcl-6和CD10定义的生发中心（GC）表型和bcl-2表达相关

获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

客服微信
服务号